Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
15:29:56 EDT Sun 05 May 2024
Enter Symbol
or Name
USA
CA



News for U:CSTL from 2023-05-04 to 2024-05-03 - 61 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2024-05-03 07:00U:CSTLNews ReleaseDecisionDx(TM)-SCC Significantly Improves Prediction Accuracy of Metastatic Events after Mohs Surgery in New Study of Patients with High-Risk Cutaneous Squamous Cell Carcinoma Tumors of the Head and Neck
2024-05-02 16:05U:CSTLNews ReleaseCastle Biosciences Reports First Quarter 2024 Results
2024-04-30 16:30U:CSTLNews ReleaseCastle Biosciences Kicks off Skin Cancer Awareness Month with a Ribbon Cutting to Celebrate the City of Friendswood's Designation as a Sun Safe Leadership Model City by IMPACT Melanoma
2024-04-11 07:00U:CSTLNews ReleaseCastle Biosciences to Release First Quarter 2024 Financial Results and Host Conference Call on Thursday, May 2, 2024
2024-04-10 17:00U:CSTLNews ReleaseCastle Biosciences Celebrates Esophageal Cancer Awareness Month through Advocacy and Educational Collaborations
2024-04-10 07:00U:CSTLNews ReleaseCastle Biosciences' Chief Financial Officer Frank Stokes Recognized as a Top CFO of Houston for Second Consecutive Year
2024-04-04 16:30U:CSTLNews ReleasePresentations at EADO Highlight Potential Impact of Castle Biosciences' DecisionDx(TM)-Melanoma and DecisionDx(TM)-SCC Tests on the Management of Patients with Skin Cancer
2024-04-02 07:00U:CSTLNews ReleaseCastle Biosciences to Present at the 23rd Annual Needham Virtual Healthcare Conference
2024-03-27 17:00U:CSTLNews ReleaseCastle Biosciences Announces Updates to its Board of Directors
2024-03-25 07:00U:CSTLNews ReleaseCastle Biosciences Earns a Top Workplaces USA Award for the Third Consecutive Year
2024-03-22 16:30U:CSTLNews ReleaseLong-term Outcomes Data Shared at SSO 2024 Show That Patients with a Low-Risk DecisionDx(TM)-Melanoma Test Result Were Recurrence Free at Three Years, Including Those Who Utilized the Test to Help Guide the Decision to Avoid an SLNB
2024-03-19 07:00U:CSTLNews ReleaseLeading Squamous Cell Carcinoma Practitioners Publish Consensus Guidelines Integrating DecisionDx(TM)-SCC into a Clinical Workflow to Improve Decision-Making Regarding the Use of Adjuvant Radiation Therapy
2024-03-15 16:30U:CSTLNews ReleaseNew Study Shows that the Drug-Drug Interactions and Lifestyle Factors Provided by Castle Biosciences' IDgenetix(TM) Test Significantly Improve Medication Recommendations Over Drug-Gene Interactions Alone for Patients 65 and Older
2024-03-12 07:00U:CSTLNews ReleaseCastle Biosciences to Present at the KeyBanc Capital Markets Virtual Life Sciences & MedTech Investor Forum
2024-03-08 16:30U:CSTLNews ReleaseCastle Biosciences to Present New Data Highlighting the Clinical Value of its Dermatologic Tests for Patients with Skin Cancer at the 2024 American Academy of Dermatology (AAD) Annual Meeting
2024-03-07 07:00U:CSTLNews ReleaseIn Novel Cohort, New Data Confirms DecisionDx(TM)-SCC Provides Significant, Independent and Clinically Actionable Risk-Stratification of Patients, Including in Various High-Risk Subgroups
2024-02-28 16:05U:CSTLNews ReleaseCastle Biosciences Reports Fourth Quarter and Full-Year 2023 Results
2024-02-26 07:00U:CSTLNews ReleaseStudy Finds DecisionDx(TM)-Melanoma Significantly Improves the Risk Stratification of Patients with Stage I Melanoma Compared to American Joint Committee on Cancer 8th Edition Staging
2024-02-07 07:00U:CSTLNews ReleaseCastle Biosciences to Release Fourth Quarter and Full-Year 2023 Financial Results and Host Conference Call on Wednesday, Feb. 28, 2024
2024-01-18 07:00U:CSTLNews ReleaseNew Study Highlights Significant Potential Medicare Savings Through Use of Castle Biosciences ¢ € ™ DecisionDx ‚ ®-SCC Test to Guide Adjuvant Radiation Therapy Decisions in Patients with Cutaneous Squamous Cell Carcinoma
2024-01-14 04:30U:CSTLNews ReleaseCastle Biosciences Presents Data Supporting the Utility of Its Tests in the Clinical Care of Patients with Skin Cancers at the 2024 Winter Clinical Dermatology Conference - Hawaii ‚ ®
2024-01-09 07:00U:CSTLNews ReleaseCastle Biosciences ¢ € ™ Chief Operating Officer Kristen Oelschlager Selected Among the Top 25 Women Leaders in Biotechnology by The Healthcare Technology Report
2024-01-07 20:00U:CSTLNews ReleaseCastle Biosciences Announces Preliminary Fourth Quarter and Full-Year 2023 Results
2023-12-20 07:00U:CSTLNews ReleaseCastle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-12-01 07:00U:CSTLNews ReleaseStudy Finds Nurse Practitioners and Physician Assistants Would Alter Patient Care Decisions Based on DecisionDx ‚ ®-Melanoma Test Results
2023-11-14 07:00U:CSTLNews ReleaseCastle Biosciences Announces Multiple Data Presentations at the 2023 American Society for Dermatologic Surgery Annual Meeting
2023-11-13 07:00U:CSTLNews ReleaseCastle Biosciences Ranked Among the Top Workplaces in Houston by the Houston Chronicle for the Third Consecutive Year
2023-11-08 16:30U:CSTLNews ReleaseReal-World Evidence Confirms IDgenetix ‚ ®-Guided Medication Management Significantly Improves Response and Remission Rates in Patients with Major Depressive Disorder
2023-11-08 13:00U:CSTLNews ReleaseCastle Biosciences to Present at Upcoming Investor Conferences
2023-11-03 07:00U:CSTLNews ReleaseCastle Announces Early Exploratory Study Data for Potential Development of a Complementary Test to Accompany DecisionDx ‚ ®-UM That Could Aid in the Early Detection of Uveal Melanomas
2023-11-02 16:06U:CSTLNews ReleaseEarly Discovery Data Shows Ability of Castle Biosciences ¢ € ™ Pipeline Program to Distinguish Between Responders and Non-Responders to an Atopic Dermatitis Therapy
2023-10-24 07:00U:CSTLNews ReleaseCastle Biosciences to Present New Data on its TissueCypher ‚ ® Barrett ¢ € ™s Esophagus Test at the 2023 American College of Gastroenterology Annual Scientific Meeting
2023-10-19 07:00U:CSTLNews ReleaseCastle Biosciences to Release Third Quarter 2023 Financial Results and Host Conference Call on Thursday, Nov. 2
2023-10-18 16:30U:CSTLNews ReleaseNew Data Highlights Clinical Utility and Performance of Castle Biosciences ¢ € ™ Dermatologic Test Portfolio at the 2023 Fall Clinical Dermatology Conference ‚ ®
2023-10-05 07:00U:CSTLNews ReleaseDecisionDx ‚ ®-Melanoma Outperforms Memorial Sloan Kettering Cancer Center (MSKCC) Nomogram in Predicting Sentinel Lymph Node Positivity in Patients with Cutaneous Melanoma
2023-10-03 07:00U:CSTLNews ReleaseCastle Biosciences Presents New Data at ASTRO 2023 Highlighting Risk-Stratification Performance of DecisionDx ‚ ®-SCC in Patients with Cutaneous Squamous Cell Carcinoma Eligible for Adjuvant Radiation Therapy
2023-10-02 07:00U:CSTLNews ReleaseCastle Biosciences Shares New Data Demonstrating Ability of TissueCypher ‚ ® Test Results to Inform Clinical Decision-Making in Patients with Non-Dysplastic Barrett ¢ € ™s Esophagus
2023-09-25 07:00U:CSTLNews ReleaseCastle Biosciences, Leading Skin Cancer Expert, Darrell Rigel, M.D., M.S., and IMPACT Melanoma Board Member to Ring Nasdaq Closing Bell on Sept. 27, 2023, to Raise Awareness of Melanoma
2023-09-14 07:00U:CSTLNews ReleaseTissueCypher ‚ ® Barrett ¢ € ™s Esophagus Test Outperformed Standard of Care in Risk-Stratifying Patients with Barrett ¢ € ™s Esophagus
2023-09-12 07:00U:CSTLNews ReleaseCastle Biosciences Announces Receipt of New York Laboratory Permit for Pittsburgh Laboratory
2023-09-09 20:00U:CSTLNews ReleaseIntegrating Drug-Drug Interactions and Lifestyle Factors with Drug-Gene Interactions Provided by Castle Biosciences ¢ € ™ IDgenetix ‚ ® Test Significantly Impacted the Number of Drug Recommendations for Patients with Moderate to Severe Depression
2023-09-08 16:30U:CSTLNews ReleaseTissueCypher ‚ ® Provides Clinically-Impactful Risk Stratification in Patients with Barrett ¢ € ™s Esophagus
2023-09-06 07:00U:CSTLNews ReleaseCastle Biosciences to Highlight Clinical Value of IDgenetix ‚ ® Test at Psych Congress 2023
2023-09-05 07:00U:CSTLNews ReleaseCastle Biosciences to Participate in Upcoming Investor Conferences
2023-08-07 07:00U:CSTLNews ReleaseNew Publication Highlights the Ability of the TissueCypher ‚ ® Barrett ¢ € ™s Esophagus Test to Improve and Standardize the Clinical Management of Low-Grade Dysplasia in Patients with Barrett ¢ € ™s Esophagus
2023-08-02 16:05U:CSTLNews ReleaseCastle Biosciences Reports Second Quarter 2023 Results
2023-08-01 07:00U:CSTLNews ReleaseCastle Biosciences to Present at the Canaccord Genuity 43rd Annual Growth Conference
2023-07-19 07:00U:CSTLNews ReleaseCastle Biosciences to Release Second Quarter 2023 Financial Results and Host Conference Call on Wednesday, Aug. 2
2023-07-18 07:00U:CSTLNews ReleaseCastle Biosciences to Host Second Annual Castle Cares Charity Walk
2023-07-17 07:00U:CSTLNews ReleaseCastle Biosciences Honored as an Arizona Top Workplace for the Second Consecutive Year
2023-07-07 07:00U:CSTLNews ReleaseCastle Biosciences to Present New DecisionDx ‚ ®-SCC and DecisionDx ‚ ®-Melanoma Data at the American Head & Neck Society ¢ € ™s (AHNS) 11th International Conference on Head and Neck Cancer
2023-06-30 07:00U:CSTLNews ReleaseStudy Data from Castle Biosciences ¢ € ™ Collaboration with the National Cancer Institute ¢ € ™s SEER Program Registries Published in JCO Precision Oncology
2023-06-20 07:00U:CSTLNews ReleaseCastle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-06-12 07:00U:CSTLNews ReleaseCastle Biosciences Presents New Data Demonstrating the Ability of DecisionDx ‚ ®-SCC to Identify Tumors Likely to Metastasize in Patients with Cutaneous Squamous Cell Carcinoma Deemed Low Risk by Traditional Staging
2023-06-05 07:00U:CSTLNews ReleaseFramework Incorporating DecisionDx ‚ ®-SCC Test Results into Clinical Decision-Making for Patients with High-Risk Cutaneous Squamous Cell Carcinoma Published in Clinical, Cosmetic and Investigational Dermatology
2023-06-03 07:00U:CSTLNews ReleaseCastle Biosciences to Share New Data on DecisionDx ‚ ®-Melanoma and DecisionDx ‚ ®-UM at the 2023 ASCO Annual Meeting
2023-05-31 07:00U:CSTLNews ReleaseIDgenetix ‚ ® Shown to Significantly Improve Medication Response and Remission Rates in Patients with Major Depressive Disorder
2023-05-30 07:00U:CSTLNews ReleaseCastle Biosciences Celebrates Skin Cancer Awareness Month
2023-05-26 07:00U:CSTLNews ReleaseCastle Biosciences ¢ € ™ Abstracts at Digestive Disease Week (DDW) Annual Meeting Selected as ¢ € œPosters of Distinction ¢ €  by the American Gastroenterological Association (AGA) Institute Council
2023-05-22 07:00U:CSTLNews ReleaseCastle Biosciences Opens New State-of-the-Art Laboratory in Pittsburgh
2023-05-15 07:00U:CSTLNews ReleaseCastle Biosciences ¢ € ™ TissueCypher ‚ ® Barrett's Esophagus Test Receives 2023 MedTech Breakthrough Award for Artificial Intelligence Innovation